Cargando…
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy
PURPOSE OF REVIEW: CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223398/ https://www.ncbi.nlm.nih.gov/pubmed/31981100 http://dx.doi.org/10.1007/s11899-020-00557-6 |